Moreover, obesity is associated with an increased risk of recurrence after treatment, advanced cancer progression and prostate cancer-specific mortality for prostate cancer patients (14, 15) Obesity and chronic hyperinsulinemia are known to reduce the production of IGFBPs and increase IGF-1 biological activity (16). Here, IGF1 is linked to obesity due to melanocortin 4 receptor deficiency.